S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:XOMA - XOMA Stock Price, Forecast & News

$23.78
+0.66 (+2.85 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$23.04
Now: $23.78
$24.45
50-Day Range
$18.81
MA: $23.10
$26.25
52-Week Range
$11.02
Now: $23.78
$26.90
Volume51,031 shs
Average Volume61,715 shs
Market Capitalization$208.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.30 million
Book Value$2.24 per share

Profitability

Net Income$-13,340,000.00

Miscellaneous

Employees11
Market Cap$208.12 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.


XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) issued its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.48) by $0.68. The biotechnology company earned $8.86 million during the quarter. XOMA had a negative return on equity of 8.93% and a negative net margin of 10.19%. View XOMA's Earnings History.

When is XOMA's next earnings date?

XOMA is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for XOMA.

What price target have analysts set for XOMA?

2 brokerages have issued 12 month price targets for XOMA's stock. Their forecasts range from $25.00 to $30.00. On average, they expect XOMA's stock price to reach $27.50 in the next year. This suggests a possible upside of 15.6% from the stock's current price. View Analyst Price Targets for XOMA.

What is the consensus analysts' recommendation for XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.

What are Wall Street analysts saying about XOMA stock?

Here are some recent quotes from research analysts about XOMA stock:
  • 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (11/9/2019)
  • 2. HC Wainwright analysts commented, "We project U.S. peak sales of $325M in 2026 for DSUVIA. For Zalviso, we project product launch in 1H20 (85% POS) with peak sales in 2027 of about $185M. We apply a 12.5% discount rate to both products." (4/12/2019)

Has XOMA been receiving favorable news coverage?

Media stories about XOMA stock have been trending positive on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. XOMA earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for XOMA.

Are investors shorting XOMA?

XOMA saw a increase in short interest in November. As of November 29th, there was short interest totalling 758,600 shares, an increase of 81.0% from the November 14th total of 419,100 shares. Based on an average daily trading volume, of 58,800 shares, the short-interest ratio is currently 12.9 days. Approximately 12.0% of the company's shares are short sold. View XOMA's Current Options Chain.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the folowing people:
  • Mr. James R. Neal, CEO & Director (Age 63)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
  • Dr. Deepshikha Datta, Chief Bus. Officer

Who are XOMA's major shareholders?

XOMA's stock is owned by many different of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.16%) and Squarepoint Ops LLC (0.14%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View Institutional Ownership Trends for XOMA.

Which institutional investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, Ness W Denman Van and Thomas M Burns. View Insider Buying and Selling for XOMA.

Which institutional investors are buying XOMA stock?

XOMA stock was bought by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal and Value Fund L P Biotechnology. View Insider Buying and Selling for XOMA.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $23.78.

How big of a company is XOMA?

XOMA has a market capitalization of $208.12 million and generates $5.30 million in revenue each year. The biotechnology company earns $-13,340,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. XOMA employs 11 workers across the globe.View Additional Information About XOMA.

What is XOMA's official website?

The official website for XOMA is http://www.xoma.com/.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]


MarketBeat Community Rating for XOMA (NASDAQ XOMA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  387 (Vote Outperform)
Underperform Votes:  373 (Vote Underperform)
Total Votes:  760
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: Equal Weight Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel